Microbicide Trials Network

LETTER OF AMENDMENT #03 TO:

MTN-024/ IPM 031
Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Female Population

Version 1.0 dated 21 March 2013

DAIDS Protocol ID: 11915

IND #: 108,743

Date of Letter of Amendment: 20 January 2015

Site Instruction

The following information impacts the MTN-024/IPM 031 study and must be forwarded to your Institutional Review Board (IRB)/Ethics Committee (EC) as soon as possible for their information and review. This must be approved by your IRB/EC before implementation. The following information also impacts the sample informed consent. Your IRB/EC will be responsible for determining the process of informing participants of the contents of this Letter of Amendment (LoA).

Implementation

Upon receiving final IRB/EC and any other applicable Regulatory Entity (RE) approval(s) for this LoA, sites should implement the LoA immediately. Sites are still required to submit a LoA registration packet to the DAIDS Protocol Registration Office (PRO) at the Regulatory Support Center (RSC). Sites will receive a registration notification for the LoA once the DAIDS PRO verifies that all the required LoA registration documents have been received and are complete. A LoA registration notification from the DAIDS PRO is not required prior to implementing the LoA. A copy of the LoA registration notification along with this letter and any IRB/EC correspondence should be retained in the site’s regulatory files.

Summary of Revisions

The purpose of this LoA is to update the listing of risks and/or discomforts associated with dapivirine vaginal rings (VRs) as reflected in the updated International Partnership for Microbicides (IPM) Investigator’s Brochure for Dapivirine Vaginal Ring, Version 9.0, 03 December 2014.

Text to be deleted is noted by strikethrough and text to be added is noted below in bold.

1. Modifications have been made to Section 13.4.1, RISKS, General, fifth paragraph, bulleted list, to reflect issuance of the updated International Partnership for Microbicides (IPM) Investigator’s Brochure, Dapivirine Vaginal Ring, Version 9.0, 03 December 2014:

Based on AEs reported among female participants in previous studies, dapivirine VRs may be associated with:

- Vaginal candidiasis
- Vaginitis bacterial
- Metrorrhagia
- Vaginal bleeding
- Headache
- Fatigue
- Vulvovaginal or genital itching
• Abdominal discomfort
• Abdominal pain
• Urinary incontinence tract infection
• Nausea
• Vaginal or genital discharge

2. APPENDIX III: SAMPLE INFORMED CONSENT FORM (SCREENING, ENROLLMENT, LONG-TERM STORAGE AND FUTURE TESTING), Risks and/or Discomforts, Risks of Study Drug, bulleted list, has been modified to reflect issuance of the updated Dapivirine Ring IB and for clarity:

Based on side effects reported among women in previous studies, dapivirine VRs vaginal rings may be associated with:

• Vaginal Yeast infection
• Vaginal bleeding at irregular intervals, particularly between your expected menstrual periods
• Headache
• Fatigue
• Vulvovaginal or genital itching
• Abdominal discomfort
• Abdominal pain
• Urinary incontinence tract infection
• Nausea
• Vaginal discharge

The above information will be incorporated into the next version of the protocol at a later time if it is amended.